CRC 12104: A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
- Type of Study
- Cancer (Oncology) - Lung
- Location
- Swedish Cancer Institute
- Short Description
Purpose: CH5424802 is a newly invented, selective oral ALK inhibitor. In the Phase II portion, the efficacy of CH5424802 will be assessed at the recommended dose.
- Status
- Open to Enrollment
- Principal Investigator
- Howard (Jack) West, M.D.
- Eligibility Notes
- ECOG performance status =< 2
- Confirmed of ALK-positive NSCLC
- No Untreated brain metastases
- No history of serious cardiac dysfunction
- No clinically significant gastrointestinal abnormality that would affect the absorption of drug
- More Info Link
- Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
- Phone
- (206) 215-3086
- CancerResearch@swedish.org
